Home Featured Page 211

Featured

Latest

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human Psyche

Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Psychedelics, and Couples Therapy

Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola

Psychedelic Bypassing: When Avoidance is Mistaken for Healing

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

The Serotonin 5-HT2A Receptor: From Mice to Humans

CaaMTech Teams Up With University of Wyoming to Study Psychedelics as...

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust)...

PT273 – Erica Rex – Clinical Trials and Spontaneous Mystical Experiences

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive...

MindMed Announces Financial Results for the Third Quarter 2021 and Business...

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

1...210211212...308 Page 211 of 308

EDITOR PICKS

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human Psyche

Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Psychedelics, and Couples Therapy

Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola

Psychedelic Bypassing: When Avoidance is Mistaken for Healing

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

The Serotonin 5-HT2A Receptor: From Mice to Humans

CaaMTech Teams Up With University of Wyoming to Study Psychedelics as...

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust)...

PT273 – Erica Rex – Clinical Trials and Spontaneous Mystical Experiences

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive...

MindMed Announces Financial Results for the Third Quarter 2021 and Business...

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

EDITOR PICKS

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY